
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Department of Pediatrics, Steele Memorial Childrens Research Center, University of Arizona, Tucson, Arizona 85724 [R. B., E. J. P., L. W.]; Arizona Cancer Center, University of Arizona, Tucson, Arizona [G. D. P-M., C. W. T.]; Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan [S. A.]; and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390 [I. J. B.]
In addition to its classic role in the cellular stress response, heat shock protein 90 (Hsp90) plays a critical but less well appreciated role in regulating signal transduction pathways that control cell growth and survival under basal, nonstress conditions. Over the past 5 years, the antitumor antibiotics geldanamycin and radicicol have become recognized as selective Hsp90-binding agents (HBA) with a novel ability to alter the activity of many of the receptors, kinases, and transcription factors involved in these cancer-associated pathways. As a consequence of their interaction with Hsp90, however, these agents also induce a marked cellular heat shock response. To study the mechanism of this response and assess its relevance to the anticancer action of the HBA, we verified that the compounds could activate a reporter construct containing consensus binding sites for heat shock factor 1 (HSF1), the major transcriptional regulator of the vertebrate heat shock response. We then used transformed fibroblasts derived from HSF1 knock-out mice to show that unlike conventional chemotherapeutics, HBA increased the synthesis and cellular levels of heat shock proteins in an HSF1-dependent manner. Compared with transformed fibroblasts derived from wild-type mice, HSF1 knock-out cells were significantly more sensitive to the cytotoxic effects of HBA but not to doxorubicin or cisplatin. Consistent with these in vitro data, we found that systemic administration of an HBA led to marked increases in the level of Hsp72 in both normal mouse tissues and human tumor xenografts. We conclude that HBA are useful probes for studying molecular mechanisms regulating the heat shock response both in cells and in whole animals. Moreover, induction of the heat shock response by HBA will be an important consideration in the clinical application of these drugs, both in terms of modulating their cytotoxic activity as well as monitoring their biological activity in individual patients.
This article has been cited by other articles:
![]() |
J. Hidalgo-de-Quintana, R. J. Evans, M. E. Cheetham, and J. van der Spuy The Leber Congenital Amaurosis Protein AIPL1 Functions as Part of a Chaperone Heterocomplex Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 2878 - 2887. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. I. Morimoto Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging Genes & Dev., June 1, 2008; 22(11): 1427 - 1438. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Trott, J. D. West, L. Klaic, S. D. Westerheide, R. B. Silverman, R. I. Morimoto, and K. A. Morano Activation of Heat Shock and Antioxidant Responses by the Natural Product Celastrol: Transcriptional Signatures of a Thiol-targeted Molecule Mol. Biol. Cell, March 1, 2008; 19(3): 1104 - 1112. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Arthur, J. D. Lich, R. K. Aziz, M. Kotb, and J. P.-Y. Ting Heat Shock Protein 90 Associates with Monarch-1 and Regulates Its Ability to Promote Degradation of NF-{kappa}B-Inducing Kinase J. Immunol., November 1, 2007; 179(9): 6291 - 6296. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Sharp, C. Prodromou, K. Boxall, M. V. Powers, J. L. Holmes, G. Box, T. P. Matthews, K.-M. J. Cheung, A. Kalusa, K. James, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues Mol. Cancer Ther., April 1, 2007; 6(4): 1198 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Weigel, S. M. Blaney, J. M. Reid, S. L. Safgren, R. Bagatell, J. Kersey, J. P. Neglia, S. P. Ivy, A. M. Ingle, L. Whitesell, et al. A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study Clin. Cancer Res., March 15, 2007; 13(6): 1789 - 1793. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. McCollum, C. J. TenEyck, B. M. Sauer, D. O. Toft, and C. Erlichman Up-regulation of Heat Shock Protein 27 Induces Resistance to 17-Allylamino-Demethoxygeldanamycin through a Glutathione-Mediated Mechanism. Cancer Res., November 15, 2006; 66(22): 10967 - 10975. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Nowakowski, A. K. McCollum, M. M. Ames, S. J. Mandrekar, J. M. Reid, A. A. Adjei, D. O. Toft, S. L. Safgren, and C. Erlichman A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6087 - 6093. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. G. Mimnaugh, W. Xu, M. Vos, X. Yuan, and L. Neckers Endoplasmic Reticulum Vacuolization and Valosin-Containing Protein Relocalization Result from Simultaneous Hsp90 Inhibition by Geldanamycin and Proteasome Inhibition by Velcade Mol. Cancer Res., September 1, 2006; 4(9): 667 - 681. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rossi, S. Ciafre, M. Balsamo, P. Pierimarchi, and M. G. Santoro Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. Cancer Res., August 1, 2006; 66(15): 7678 - 7685. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Yetik-Anacak, T. Xia, C. Dimitropoulou, R. C. Venema, and J. D. Catravas Effects of hsp90 binding inhibitors on sGC-mediated vascular relaxation Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H260 - H268. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Thomas, J. M. Harrell, Y. Morishima, H.-M. Peng, W. B. Pratt, and A. P. Lieberman Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction Hum. Mol. Genet., June 1, 2006; 15(11): 1876 - 1883. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Neal, S. Karunanithi, A. Best, A. K.-C. So, R. M. Tanguay, H. L. Atwood, and J. T. Westwood Thermoprotection of synaptic transmission in a Drosophila heat shock factor mutant is accompanied by increased expression of Hsp83 and DnaJ-1 Physiol Genomics, May 16, 2006; 25(3): 493 - 501. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sanderson, M. Valenti, S. Gowan, L. Patterson, Z. Ahmad, P. Workman, and S. A. Eccles Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol. Cancer Ther., March 1, 2006; 5(3): 522 - 532. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Zaarur, V. L. Gabai, J. A. Porco Jr., S. Calderwood, and M. Y. Sherman Targeting Heat Shock Response to Sensitize Cancer Cells to Proteasome and Hsp90 Inhibitors Cancer Res., February 1, 2006; 66(3): 1783 - 1791. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Guo, K. Rocha, P. Bali, M. Pranpat, W. Fiskus, S. Boyapalle, S. Kumaraswamy, M. Balasis, B. Greedy, E. S. M. Armitage, et al. Abrogation of Heat Shock Protein 70 Induction as a Strategy to Increase Antileukemia Activity of Heat Shock Protein 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin Cancer Res., November 15, 2005; 65(22): 10536 - 10544. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. L. Vega and A. De Maio Increase in Phagocytosis after Geldanamycin Treatment or Heat Shock: Role of Heat Shock Proteins J. Immunol., October 15, 2005; 175(8): 5280 - 5287. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Turbyville, E.M. K. Wijeratne, L. Whitesell, and A.A. L. Gunatilaka The anticancer activity of the fungal metabolite terrecyclic acid A is associated with modulation of multiple cellular stress response pathways Mol. Cancer Ther., October 1, 2005; 4(10): 1569 - 1576. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Westerheide and R. I. Morimoto Heat Shock Response Modulators as Therapeutic Tools for Diseases of Protein Conformation J. Biol. Chem., September 30, 2005; 280(39): 33097 - 33100. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, et al. Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90: A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS J. Biol. Chem., July 22, 2005; 280(29): 26729 - 26734. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Price, J. M.W. Quinn, N. A. Sims, J. Vieusseux, K. Waldeck, S. E. Docherty, D. Myers, A. Nakamura, M. C. Waltham, M. T. Gillespie, et al. The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line Cancer Res., June 1, 2005; 65(11): 4929 - 4938. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Auluck, M. C. Meulener, and N. M. Bonini Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila J. Biol. Chem., January 28, 2005; 280(4): 2873 - 2878. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Westerheide, J. D. Bosman, B. N. A. Mbadugha, T. L. A. Kawahara, G. Matsumoto, S. Kim, W. Gu, J. P. Devlin, R. B. Silverman, and R. I. Morimoto Celastrols as Inducers of the Heat Shock Response and Cytoprotection J. Biol. Chem., December 31, 2004; 279(53): 56053 - 56060. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bagatell and L. Whitesell Altered Hsp90 function in cancer: A unique therapeutic opportunity Mol. Cancer Ther., August 1, 2004; 3(8): 1021 - 1030. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. G. Mimnaugh, W. Xu, M. Vos, X. Yuan, J. S. Isaacs, K. S. Bisht, D. Gius, and L. Neckers Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity Mol. Cancer Ther., May 1, 2004; 3(5): 551 - 566. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Cox and C. A. Miller III Pharmacological and Genetic Analysis of 90-kDa Heat Shock Isoprotein-Aryl Hydrocarbon Receptor Complexes Mol. Pharmacol., December 1, 2003; 64(6): 1549 - 1556. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bagatell, O. Khan, G. Paine-Murrieta, C. W. Taylor, S. Akinaga, and L. Whitesell Destabilization of Steroid Receptors by Heat Shock Protein 90-binding Drugs: A Ligand-independent Approach to Hormonal Therapy of Breast Cancer Clin. Cancer Res., July 1, 2001; 7(7): 2076 - 2084. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Hostein, D. Robertson, F. DiStefano, P. Workman, and P. Andrew Clarke Inhibition of Signal Transduction by the Hsp90 Inhibitor 17-Allylamino-17-demethoxygeldanamycin Results in Cytostasis and Apoptosis Cancer Res., May 1, 2001; 61(10): 4003 - 4009. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |